122 related articles for article (PubMed ID: 21544077)
1. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects.
Kusuhara H; Ito S; Kumagai Y; Jiang M; Shiroshita T; Moriyama Y; Inoue K; Yuasa H; Sugiyama Y
Clin Pharmacol Ther; 2011 Jun; 89(6):837-44. PubMed ID: 21544077
[TBL] [Abstract][Full Text] [Related]
2. The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future.
Roffel AF; van Hoogdalem EJ
Front Pharmacol; 2024; 15():1369079. PubMed ID: 38562464
[TBL] [Abstract][Full Text] [Related]
3. N-methylnicotinamide is an endogenous probe for evaluation of drug-drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K).
Ito S; Kusuhara H; Kumagai Y; Moriyama Y; Inoue K; Kondo T; Nakayama H; Horita S; Tanabe K; Yuasa H; Sugiyama Y
Clin Pharmacol Ther; 2012 Nov; 92(5):635-41. PubMed ID: 23047651
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the multidrug and toxin extrusion (MATE) transporter by pyrimethamine increases the plasma concentration of metformin but does not increase antihyperglycaemic activity in humans.
Oh J; Chung H; Park SI; Yi SJ; Jang K; Kim AH; Yoon J; Cho JY; Yoon SH; Jang IJ; Yu KS; Chung JY
Diabetes Obes Metab; 2016 Jan; 18(1):104-8. PubMed ID: 26381793
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers.
Morrissey KM; Stocker SL; Chen EC; Castro RA; Brett CM; Giacomini KM
Clin Pharmacokinet; 2016 Apr; 55(4):495-506. PubMed ID: 26507723
[TBL] [Abstract][Full Text] [Related]
6. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
Müller F; Pontones CA; Renner B; Mieth M; Hoier E; Auge D; Maas R; Zolk O; Fromm MF
Eur J Clin Pharmacol; 2015 Jan; 71(1):85-94. PubMed ID: 25552403
[TBL] [Abstract][Full Text] [Related]
7. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
Ito S; Kusuhara H; Yokochi M; Toyoshima J; Inoue K; Yuasa H; Sugiyama Y
J Pharmacol Exp Ther; 2012 Feb; 340(2):393-403. PubMed ID: 22072731
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Wittwer MB; Zur AA; Khuri N; Kido Y; Kosaka A; Zhang X; Morrissey KM; Sali A; Huang Y; Giacomini KM
J Med Chem; 2013 Feb; 56(3):781-795. PubMed ID: 23241029
[TBL] [Abstract][Full Text] [Related]
9. Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.
Grün B; Kiessling MK; Burhenne J; Riedel KD; Weiss J; Rauch G; Haefeli WE; Czock D
Br J Clin Pharmacol; 2013 Nov; 76(5):787-96. PubMed ID: 23305245
[TBL] [Abstract][Full Text] [Related]
10. Reduction of metformin renal tubular secretion by cimetidine in man.
Somogyi A; Stockley C; Keal J; Rolan P; Bochner F
Br J Clin Pharmacol; 1987 May; 23(5):545-51. PubMed ID: 3593625
[TBL] [Abstract][Full Text] [Related]
11. Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins.
Kato K; Mori H; Kito T; Yokochi M; Ito S; Inoue K; Yonezawa A; Katsura T; Kumagai Y; Yuasa H; Moriyama Y; Inui K; Kusuhara H; Sugiyama Y
Pharm Res; 2014 Jan; 31(1):136-47. PubMed ID: 23907530
[TBL] [Abstract][Full Text] [Related]
12. Development of a Support Vector Machine-Based System to Predict Whether a Compound Is a Substrate of a Given Drug Transporter Using Its Chemical Structure.
Ose A; Toshimoto K; Ikeda K; Maeda K; Yoshida S; Yamashita F; Hashida M; Ishida T; Akiyama Y; Sugiyama Y
J Pharm Sci; 2016 Jul; 105(7):2222-30. PubMed ID: 27262201
[TBL] [Abstract][Full Text] [Related]
13. Four cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers.
Han TK; Proctor WR; Costales CL; Cai H; Everett RS; Thakker DR
J Pharmacol Exp Ther; 2015 Mar; 352(3):519-28. PubMed ID: 25563903
[TBL] [Abstract][Full Text] [Related]
14. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.
Stocker SL; Morrissey KM; Yee SW; Castro RA; Xu L; Dahlin A; Ramirez AH; Roden DM; Wilke RA; McCarty CA; Davis RL; Brett CM; Giacomini KM
Clin Pharmacol Ther; 2013 Feb; 93(2):186-94. PubMed ID: 23267855
[TBL] [Abstract][Full Text] [Related]
15. Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions.
Burt HJ; Neuhoff S; Almond L; Gaohua L; Harwood MD; Jamei M; Rostami-Hodjegan A; Tucker GT; Rowland-Yeo K
Eur J Pharm Sci; 2016 Jun; 88():70-82. PubMed ID: 27019345
[TBL] [Abstract][Full Text] [Related]
16. Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates.
Hacker K; Maas R; Kornhuber J; Fromm MF; Zolk O
PLoS One; 2015; 10(9):e0136451. PubMed ID: 26327616
[TBL] [Abstract][Full Text] [Related]
17. Role of organic cation transporters in drug-drug interaction.
Koepsell H
Expert Opin Drug Metab Toxicol; 2015; 11(10):1619-33. PubMed ID: 26206523
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Organic Anion Transporter 2 (SLC22A7): A Highly Efficient Transporter for Creatinine and Species-Dependent Renal Tubular Expression.
Shen H; Liu T; Morse BL; Zhao Y; Zhang Y; Qiu X; Chen C; Lewin AC; Wang XT; Liu G; Christopher LJ; Marathe P; Lai Y
Drug Metab Dispos; 2015 Jul; 43(7):984-93. PubMed ID: 25904762
[TBL] [Abstract][Full Text] [Related]
19. Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110.
Zhang Y; Warren MS; Zhang X; Diamond S; Williams B; Punwani N; Huang J; Huang Y; Yeleswaram S
Drug Metab Dispos; 2015 Apr; 43(4):485-9. PubMed ID: 25605813
[TBL] [Abstract][Full Text] [Related]
20. Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers.
Cho SK; Kim CO; Park ES; Chung JY
Br J Clin Pharmacol; 2014 Dec; 78(6):1426-32. PubMed ID: 25060604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
